Skip to content

A clinical study for validity and provision method of periodontal tissue regeneration with autologous adipose derived stem cells and platelet rich plasma

A clinical study for validity and provision method of periodontal tissue regeneration with autologous adipose derived stem cells and platelet rich plasma - Periodontal tissue regeneration using adipose derived stem cells and platelet rich plasma

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTb030190173
Enrollment
15
Registered
2020-01-06
Start date
2019-06-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

periodontitis

Interventions

Subcutaneous adipose tissue and blood collection, administration of cell processing products

Sponsors

Tobita Morikuni
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Have a Periodontal pocket more than 5 mm at baseline examination. 2. Intrabony defect is 5 mm and more depth, and 2 mm and more width at interproximal site of the experimental tooth by X-ray examination. 3. Already have received initial preparation at the screening. 4. Mobility of experimental tooth is 0, 1, or 2, and exist keratinized gingiva. 5. Good oral health. 6. Subcutaneous fat tissue can be harvest normally and safely 7. 20 years and older. 8. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Can not be measured clinical attachment level of experimental tooth. 2. Have a history of Complicate malignant tumor. 3. Suspected of oral malignant tumor or precancerous lesion. 4. Need to undergo the treatment, such as surgical treatment, restorative treatment or root canal treatment, at the experimental tooth within 36 weeks after transplant. 5. Pregnancy, during breastfeeding, or possibility of pregnancy. 6. Have serious cardiac diseases. 7. Have serious liver diseases. 8. Have end-stage renal diseases or on hemodialysis. 9. Serious coagulopathies. 10. Hemoglobin A1c is more than 6.8% at the screening. 11. Have active infectious diseases. 12. Alcoholism or Drug dependence. 13. Mental or consciousness disorder. 14. HCV antibody, HBs antigen, ATLA virus antibody or HIV antibody positive person. 15. Smoke more than 10 pieces per day. 16. Other, the investigator believes makes him/her unsuitable for participation in the clinical study.

Design outcomes

Primary

MeasureTime frame
efficacy

Secondary

MeasureTime frame
Safety

Countries

Japan

Contacts

Public ContactYosuke Masubuchi

Juntendo University

y-masubuchi@juntendo.ac.jp+81-3-3814-5672

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026